科研之友
微信
新浪微博
Facebook
分享链接
摘要
A passive equilibrationmethodwhich relies on addition of candidate drugs to pre-formed liposomes is described as an alternativemethod for preparing liposome encapsulated drugs. The method is simple, rapid and applicable to liposomes prepared with high (45 mol%) or low (<20 mol%) levels of cholesterol. Passive equilibration is performed in 4-steps: (i) formation of liposomes, (ii) addition of the candidate drug to the liposomes in combination with a permeability enhancing agent, (iii) incubation at a temperature that facilitates diffusion of the added compound across the lipid bilayer, and (iv) quenching the enhancedmembrane permeability by reduction in temperature and/or removal of the permeabilization enhancer. Themethod is fully exemplified here using ethanol as the permeabilization enhancer and carboplatin (CBDCA) as the drug candidate. It is demonstrated that ethanol can be added to liposomes prepared with 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and Cholesterol (Chol) (55: 45 mol ratio) in amounts up to 30% (v/v) with no change in liposome size, even when incubated at temperatures > 60 degrees C. Super-saturated solutions of CBDCA (40 mg/mL) can be prepared at 70 degrees C and these are stable in the presence of ethanol even when the temperature is reduced to <30 degrees C. maximum CBDCA encapsulation is achieved within 1 h after the CBDCA solution is added to pre-formed DSPC/Chol liposomes in the presence of 30% (v/v) ethanol at 60 degrees C. When the pre-formed liposomes are mixed with ethanol (30% v/v) at or below 40 degrees C, the encapsulation efficiency is reduced by an order of magnitude. The method was also applied to liposomes prepared from other compositions include a cholesterol free formulations (containing 1,2-distearoyl-snglycero-3-phosphoethanolamine-N-[carboxy(polyethyleneglycol)-2000] (DSPE-PEG2000)) and a low Chol (<20 mol%) formulations prepared with the distearoyl-sn-glycero-3-phospho-(1'-rac-glycerol) DSPG)). The cytotoxic activity of CBDCA was unaffected when prepared in this manner and two of the resultant formulations exhibited good stability in vitro and in vivo. The cytotoxic activity of CBDCA was unaffected when prepared in this manner and the resultant formulations exhibited good stability in vitro and in vivo. Pharmacokinetics studies in CD-1 mice indicated that the resulting formulations increased the circulation half life of the associated CBDCA significantly (AUC0-24 h of CBDCA = 0.016 mu g . hr/mL; AUC(0-24h) of the DSPC/Chol CBDCA formulation = 1014.0 mu g . hr/mL and AUC0-24h of the DSPC/DSPG/Chol CBDCA formulation= 583.96 mu g . hr/mL). Preliminary efficacy studies in Rag-2M mice with established subcutaneous H1975 and U-251 tumors suggest that the therapeutic activity of CBDCA is improved when administered in liposomal formulations. The encapsulation method described here has not been disclosed previously and will have broad applications to drugs that would normally be encapsulated during liposome manufacturing.
- 出版日期2017-4-28
